INTRODUCTION
Neuroendocrine tumors (NETs) are rare and complex neoplasms with increasing incidence and prevalence worldwide.1

OBJECTIVE
SCAN assessed global provision of NET diagnostics and treatment in terms of:

- Awareness
- Quality of servicing
- Availability
- Affordability

This analysis focused on early diagnosis of NET patients with colonic and rectal primary NET.

METHODS
During Sept-Nov 2019, NET patients and healthcare professionals (HCP) completed an online survey

- The survey was disseminated via social media and NET patient groups’ and medical societies’ networks.
- The survey was available in 14 languages: Arabic, Bulgarian, English, German, Dutch/Flemish, French, Japanese, Hindi, Italian, Mandarin (Chinese), Portuguese, Russian, Spanish, and Swahili.

PARTICIPANT CHARACTERISTICS
- 2359 NET patients and 436 HCPs from 68 countries responded.
- 7% [153/2359] were diagnosed with primary NET of the colon [39% (59/153)] and the rectum [61% (94/153)] (Figure 1).
- Average colorectal NET patient age at the time of diagnosis was 51 years with an average of 4 years living with the disease.

RESULTS

NET Staging and Misdiagnosing
- Every third colorectal NET patient had stage IV NET at diagnosis (32% [49/153]), colonic NET patients diagnosed with stage IV were 51% (30/58), rectal NET patients diagnosed with stage IV were 20% (19/97).
- Slightly above a third reported they were misdiagnosed at least once with another condition prior to receiving the correct diagnosis (34% [52/153]).

Figure 2: Years between first symptom and diagnosis for those initially misdiagnosed [N=52]

- Mean time to correct diagnosis for the misdiagnosed was 4.16 years (N=52). A third were misdiagnosed for more than 5 years (Figure 2).
- The most common misdiagnosed conditions were gastritis (54% [28/52]) and Irritable Bowel Syndrome (IBS) (50% [26/52]).
- NET was discovered incidentally while testing for another condition in another third of the cases (31% [48/153]).
- Only in 31% of patients, colorectal NET was the first diagnosis received after initial symptoms.

Diagnostics
- The diagnostic tools that most often led to the correct diagnosis were biopsy (65% [98/153] and colonoscopy (47% [71/153]). (Figure 3).

Figure 3: Diagnostic tools that lead to correct colorectal NET diagnosis [N=153]

HCP involvement
- The clinicians who most commonly suggested the test were gastroenterologists (34% [54/153]) or surgeons (20% [30/153]).
- The majority of colorectal NET patients received their diagnosis at a hospital without a NET specialist (41% [62/153]) (Figure 4).

Figure 4: Place where diagnosis was received [N=153]

- A private medical practice
  - Medical center
  - Medical center specialized in NETs (like NET Center of Excellence)
  - A hospital without a NET specialist
  - A hospital with a NET specialist but not with a specialized center in NETs
  - Other

RESULTS [cont.]

Issues and recommendations
- The most frequent issues reported by colorectal NET patients were ‘lack of experts to provide first or second opinion on their case’ (22% [23/105]) and ‘lack of access to reliable information about their NET’ (19% [20/105]).
- Most common recommendations made by colorectal NET patients with regards to improving NET care were ‘better access to NET experts/specialist centres’ (66% [101/153]) and ‘more HCPs knowledgeable in NETs’ (60% [91/153]).

CONCLUSION
- SCAN represents the biggest global compendium of data about NETs extant.
- Misdiagnosis and incidental diagnosis lead to an extremely high proportion of NET patients diagnosed with stage IV, associated with poorer patient outcomes and remains a global challenge.
- Key requirements to further drive forward improvements in global NETs care include:
  - More knowledge about NETs among colorectal medical specialists is vital for early detection and timely referral for proper testing

REFERENCES

ACKNOWLEDGEMENTS

INCA would like to thank all its members as well as its partners: ENETS (European Neuroendocrine Tumor Society), NANECS (North American Neuroendocrine Cancer Society), APNETS (Asia-Pacific Neuroendocrine Society), CommNETS (Commonwealth Neuroendocrine Tumor Group), JNETS (Japan Neuroendocrine Tumor Society), CNETS (Chinese Neuroendocrine Tumor Society), UICC (Fusion for International Cancer Control), EURORDIS (European Organisation for Rare Diseases), NORD (National Organization for Rare Disorders) and ECCO (European Cancer Organisation) and many others for their instrumental support of this global effort. INCA would also like to thank its industry supporters: Ipsen, JTV and Novartis.

Strategent Ltd, Winchester, UK provided editorial support to the authors.

POSTER CATEGORY: CLINICAL NEUROENDOCRINE TUMOURS

European Colorectal Congress, 29 November - 2 December 2020 Virtual